The Hill
The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest step by the Trump administration toward possible approval.
The agency did not disclose the specific companies that were granted priority review vouchers. Two companies are studying psilocybin; one for treatment-resistant depression (TRD) and the other for treatment of major depressive disorder.
A third company is studying methylone, a drug similar to MDMA, for PTSD.
READ THE FULL STORYÂ
